Anil R. Diwan, PhD, is president and chairman of NanoViricides, Inc., a publicly traded company dedicated to advancing antiviral applications of a novel nanomedicines platform with the potential for creating drugs that the virus cannot escape by virtue of genomic changes, (mutations, recombinations, re-assortments) that are common in the virus world. He founded his own private company and began working in nanomedicines circa 1992. There he invented "TheraCour®" polymeric micelle zip-code-like targeting and encapsulating drug delivery platform. With his colleagues at AllExcel, Inc., he has also co-developed a novel cell therapy that promises to be a cure for Parkinson’s Disease. Dr. Diwan received his first US patent in nanomedicines in 2004. Further advancements have already resulted in three international PCT applications that have matured into a number of patents worldwide. Dr. Diwan co-founded NanoViricides, Inc., in 2005 and played a key role in its up-listing NYSE-American exchange in 2013. He has been instrumental in raising over $100 million at NanoViricides since founding it. He was also instrumental in the design and architecture of the new NanoViricides campus in Shelton, CT with discovery-to-cGMP-manufacture capabilities under one roof. Dr. Diwan was recognized as "2014 Researcher of the Year" by BusinessNewHaven and NewHaven Register group, which provides annual recognitions for outstanding individuals in Connecticut state.
Dr. Diwan obtained his BS in chemical engineering from the Indian Institute of Technology, Bombay, India, in 1980. Acceptance to the Indian Institute of Technology is based on the ultra-competitive Joint Entrance Examination. Dr. Diwan stood 9th nationally in this examination. Following his undergraduate degree, he obtained his PhD in (bio)chemical engineering in 1986 from Rice University, Houston, USA.